MKI67 and neoplasm: As shown in Fig. 6D, the percentage of Ki67-positive proliferating tumor cells was lower in the BMS-794833 and anlotinib groups than in the control group, with the combination therapy group exhibiting the lowest proportion of Ki67-positive cells.